- Home
- SMTC vs MRUS Comparison
SMTC vs MRUS Comparison
Compare SMTC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTC
- MRUS
- Stock Information
- Founded
- SMTC 1960
- MRUS 2003
- Country
- SMTC United States
- MRUS Netherlands
- Employees
- SMTC N/A
- MRUS 260
- Industry
- SMTC Semiconductors
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SMTC Technology
- MRUS Health Care
- Exchange
- SMTC Nasdaq
- MRUS Nasdaq
- Market Cap
- SMTC 3.2B
- MRUS 4.1B
- IPO Year
- SMTC N/A
- MRUS 2016
- Fundamental
- Price
- SMTC $41.88
- MRUS $53.11
- Analyst Decision
- SMTC Strong Buy
- MRUS Strong Buy
- Analyst Count
- SMTC 12
- MRUS 12
- Target Price
- SMTC $60.08
- MRUS $87.92
- AVG Volume (30 Days)
- SMTC 2.2M
- MRUS 2.0M
- Earning Date
- SMTC 05-27-2025
- MRUS 07-31-2025
- Dividend Yield
- SMTC N/A
- MRUS N/A
- EPS Growth
- SMTC N/A
- MRUS N/A
- EPS
- SMTC N/A
- MRUS N/A
- Revenue
- SMTC $954,242,000.00
- MRUS $54,732,000.00
- Revenue This Year
- SMTC $15.81
- MRUS $75.57
- Revenue Next Year
- SMTC $9.21
- MRUS $31.84
- P/E Ratio
- SMTC N/A
- MRUS N/A
- Revenue Growth
- SMTC 13.83
- MRUS 42.77
- 52 Week Low
- SMTC $24.05
- MRUS $33.19
- 52 Week High
- SMTC $79.52
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- SMTC 61.05
- MRUS 53.18
- Support Level
- SMTC $39.97
- MRUS $52.41
- Resistance Level
- SMTC $42.60
- MRUS $54.59
- Average True Range (ATR)
- SMTC 1.73
- MRUS 2.15
- MACD
- SMTC 0.05
- MRUS -0.77
- Stochastic Oscillator
- SMTC 84.63
- MRUS 7.62
About SMTC Semtech Corporation
Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems and IoT Connected Services. The majority of the company's revenue is earned through Analog Mixed Signal and Wireless segment. Geographically majority of the company's revenue is earned from Asia Pacific region, company also operates in North America and Europe.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.